Low-Level Laser for Mitigation of Low Salivary Flow Rate in Head and Neck Cancer Patients Undergoing Radiochemotherapy: A Prospective Longitudinal Study
Restricted accessResearch articleFirst published online August, 2016
Low-Level Laser for Mitigation of Low Salivary Flow Rate in Head and Neck Cancer Patients Undergoing Radiochemotherapy: A Prospective Longitudinal Study
Objective: The present study aimed to assess the impact of low-level laser (LLL) on low salivary flow rate in patients undergoing radiochemotherapy (RT-CT) for head and neck cancer. Background data: LLL has shown efficiency in preventing hyposalivation in patients under different pathological conditions, including those undergoing RT-CT. Methods: During all RT-CT, 17 patients received laser therapy and 10 received clinical care only. An Indium-Gallium-Aluminum-Phosphorus diode laser was punctually used for intraoral (660 nm, 40 mW, 10 J/cm2, illuminated area 0.04 cm2, 10 sec) and extraoral irradiation (780 nm, 15 mW, 3.8 J/cm2, illuminated area 0.04 cm2, 10 sec), three times a week and on alternate days, for a total of 21 sessions. Unstimulated salivary flow rate was assessed before the first RT session (N0), at the 15th RT session (N15), at the last RT session (Nf), and at 30 (N30) and 90 days after the end of the oncologic treatment (N90). Results: At N15, Nf, and N30, patients treated with LLL showed significantly higher averages of salivary flow rate when compared with patients receiving clinical care only. Conclusions: LLL seems to be an efficient tool for mitigation of salivary hypofunction in patients undergoing RT for head and neck cancer.
Get full access to this article
View all access options for this article.
References
1.
JellemaAP, SlotmanBJ, DoornaertP, LeemansCR, LangendijkJA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys, 2007; 69:751–760.
2.
RoesinkJM, MoerlandMA, BattermannJJ, HordijkGJ, TerhaardCH. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys, 2001; 51:938–946.
3.
RubiraCM, DevidesNJ, UbedaLT, et al.Evaluation of some oral postradiotherapy sequelae in patients treated for head and neck tumors. Braz Oral Res, 2007; 21:272–277.
KarbachJ, WalterC, Al-NawasB. Evaluation of saliva flow rates, Candida colonization and susceptibility of Candida strains after head and neck radiation. Clin Oral Investig, 2012; 16:1305–1312.
6.
JensenSB, PedersenAM, ReibelJ, NauntofteB. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer, 2003; 11:207–225.
7.
EisbruchA, RhodusN, RosenthalD, et al.How should we measure and report radiotherapy-induced xerostomia?. Semin Radiat Oncol, 2003; 13:226–234.
8.
BurlageFR, RoesinkJM, KampingaHH, et al.Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys, 2008; 70:14–22.
9.
BurlageFR, FaberH, KampingaHH, LangendijkJA, VissinkA, CoppesRP. Enhanced proliferation of acinar and progenitor cells by prophylactic pilocarpine treatment underlies the observed amelioration of radiation injury to parotid glands. Radiother Oncol, 2009; 90:253–256.
10.
JhamBC, TeixeiraIV, AboudCG, CarvalhoAL, Coelho MdeM, FreireAR. A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer. Oral Oncol, 2007; 43:137–142.
11.
VissinkA, MitchellJB, BaumBJ, et al.Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys, 2010; 78:983–991.
12.
BuentzelJ, MickeO, AdamietzIA, MonnierA, GlatzelM, de VriesA. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys, 2006; 64:684–691.
13.
LafaurieG, FedeleS, LópezRM, et al.Biotechnological advances in neuro-electro-stimulation for the treatment of hyposalivation and xerostomia. Med Oral Patol Oral Cir Bucal, 2009; 14:E76–E80.
14.
FornerL, HyldegaardO, von BrockdorffAS, et al.Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study. Oral Oncol, 2011; 47:546–551.
15.
LopesCO, MasJRI, ZângaroRA. Low level laser therapy in the prevention of radiotherapy-induced xerostomia and oral mucositis [Translation]. Radiol Bras, 2006; 39:131–136.
16.
CamposL, SimõesA, SáPH, Eduardo C deP. Improvement in quality of life of an oncological patient by laser phototherapy. Photomed Laser Surg, 2009; 27:371–374.
17.
Vidović JurasD, LukacJ, Cekić–ArambasinA, et al.Effects of low-level laser treatment on mouth dryness. Coll Antropol, 2010; 34:1039–1043.
18.
SimõesA, de CamposL, de SouzaDN, de MatosJA, FreitasPM, NicolauJ. Laser phototherapy as topical prophylaxis against radiation-induced xerostomia. Photomed Laser Surg, 2010; 28:357–363.
19.
LallaRV, BowenJ, BaraschA, et al.MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014; 120:1453–1461.
20.
SimõesA, NicolauJ, de SouzaDN, et al.Effect of defocused infrared diode laser on salivary flow rate and some salivary parameters of rats. Clin Oral Investig, 2008; 12:25–30.
21.
OnizawaK, MuramatsuT, MatsukiM, et al.Low-level (gallium-aluminum-arsenide) laser irradiation of Par-C10 cells and acinar cells of rat parotid gland. Lasers Med Sci, 2009; 24:155–161.
22.
Radiation Therapy Oncology Group. A phase III study to test the efficacy of the prophylatic use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy in head and neck cancer patients. RTOG97-09. Philadelphia: Radiation Therapy Oncology Group, 1999.
23.
de Barros PontesC, PolizelloAC, SpadaroAC. Clinical and biochemical evaluation of the saliva of patients with xerostomia induced by radiotherapy. Braz Oral Res, 2004; 18:69–74.
24.
DeboniAL, GiordaniAJ, LopesNN, et al.Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Support Care Cancer, 2012; 20:2903–2911.
25.
SchartingerVH, GalvanO, RiechelmannH, DudásJ. Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy. Support Care Cancer, 2012; 20:523–529.
26.
SperandioFF, GiudiceFS, CorrêaL, PintoDSJr, HamblinMR, de SousaSC. Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway. J Biophotonics, 2013; 6:839–847.
27.
Gomes HenriquesÁC, GinaniF, OliveiraRM, et al.Low-level laser therapy promotes proliferation and invasion of oral squamous cell carcinoma cells. Lasers Med Sci, 2014; 29:1385–1395.
